Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle ...

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement ...

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...

The California biotech has one therapy in Phase 1 testing and expects another to advance to the clinic later this year.

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

The estimated 6,000 women a day who reach menopause experience it differently. Some have debilitating, vasomotor symptoms ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, ...

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a ...

The drug, which Invivyd sees as a potential treatment and “targeted alternative” for the vaccine-hesitant, comes as measles ...